XENE — Xenon Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $3.01bn
- $2.37bn
- 43
- 30
- 60
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.24 | ||
| Price to Tang. Book | 3.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -22.83% | ||
| Return on Equity | -22.12% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.83 | 32.17 | 18.44 | 9.43 | n/a | 2.39 | 5.64 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Xenon Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company focused on developing therapeutics to improve the lives of patients with neurological disorders, with a focus on epilepsy. The Company’s product pipeline includes XEN1101 (Focal Onset Seizures), XEN1101 (Primary Generalized Tonic-Clonic Seizures), XEN1101 (Major Depressive Disorder) and NBI-921352 (NEUROCRINE). It is developing XEN1101, a differentiated Kv7 potassium channel opener, for the treatment of epilepsy, MDD and potentially other neurological disorders. Its XEN1101 Phase III epilepsy program includes two identical Phase III clinical trials, called X-TOLE2 and X-TOLE3, that are designed closely after the Phase IIb X-TOLE clinical trial. Its Phase III X-ACKT clinical trial is intended to support potential regulatory submissions in an additional epilepsy indication of primary generalized tonic-clonic seizures (PGTCS).
Directors
- Simon Pimstone CHM (53)
- Ian Mortimer PRE (45)
- Sherry Aulin CFO (37)
- James Empfield EVP (60)
- Robin Sherrington EVP (60)
- Christopher Von Seggern OTH (42)
- Dawn Svoronos LED (67)
- Mohammad Azab IND (65)
- Clarissa Desjardins IND (54)
- Steven Gannon IND (59)
- Michael Hayden IND (69)
- Frank Holler IND (64)
- Patrick Machado IND (57)
- Gary Patou IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 17th, 2000
- Public Since
- October 17th, 2014
- No. of Shareholders
- 82
- No. of Employees
- 251
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 75,432,482
- Address
- 3650 Gilmore Way, VANCOUVER, V5G 4W8
- Web
- https://www.xenon-pharma.com/
- Phone
- +1 6044843300
- Auditors
- KPMG LLP
Upcoming Events for XENE
Xenon Pharmaceuticals Inc Annual Shareholders Meeting
Xenon Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Xenon Pharmaceuticals Inc Earnings Release
Similar to XENE
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Xenon Pharmaceuticals share price?
As of Today at 19:24 UTC, shares in Xenon Pharmaceuticals are trading at $39.88. This share price information is delayed by 15 minutes.
How has the Xenon Pharmaceuticals share price performed this year?
Shares in Xenon Pharmaceuticals last closed at $39.88 and the price had moved by +4.4% over the past 365 days. In terms of relative price strength the Xenon Pharmaceuticals share price has underperformed the S&P500 Index by -13.12% over the past year.
What are the analyst and broker recommendations for Xenon Pharmaceuticals?
The overall consensus recommendation for Xenon Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Xenon Pharmaceuticals dividend yield?
Xenon Pharmaceuticals does not currently pay a dividend.
Does Xenon Pharmaceuticals pay a dividend?
Xenon Pharmaceuticals does not currently pay a dividend.
When does Xenon Pharmaceuticals next pay dividends?
Xenon Pharmaceuticals does not currently pay a dividend.
How do I buy Xenon Pharmaceuticals shares?
To buy shares in Xenon Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Xenon Pharmaceuticals?
As of the previous close price of $39.88, shares in Xenon Pharmaceuticals had a market capitalisation of $3.01bn.
Where are Xenon Pharmaceuticals shares listed?
Here are the trading details for Xenon Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: XENE
What kind of share is Xenon Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Xenon Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Xenon Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Xenon Pharmaceuticals is $58.10. That is 45.69% above the last closing price of $39.88.
Analysts covering Xenon Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.91 for the next financial year.
What is the trend in the Xenon Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Xenon Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +1.86%.
As of the last closing price of $39.88, shares in Xenon Pharmaceuticals were trading +0.48% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Xenon Pharmaceuticals PE Ratio?
The Xenon Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $39.88.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Xenon Pharmaceuticals?
Xenon Pharmaceuticals' management team is headed by:
- Simon Pimstone - CHM
- Ian Mortimer - PRE
- Sherry Aulin - CFO
- James Empfield - EVP
- Robin Sherrington - EVP
- Christopher Von Seggern - OTH
- Dawn Svoronos - LED
- Mohammad Azab - IND
- Clarissa Desjardins - IND
- Steven Gannon - IND
- Michael Hayden - IND
- Frank Holler - IND
- Patrick Machado - IND
- Gary Patou - IND